{"entity":{"id":"nct04538742","kind":"trial","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of Trastuzumab deruxtecan, Durvalumab, Pertuzumab and Tucatinib in HER2-positive breast cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT04538742 by AstraZeneca, with 245 participants enrolled, started 2020-12-28 and due to reach its primary completion in 2025-01-31. Interventions recorded: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Pertuzumab and Tucatinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04538742","url":"https://clinicaltrials.gov/study/NCT04538742"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan","durvalumab","pertuzumab","tucatinib"],"companies":["astrazeneca","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04538742","phase":"1/2","setting":"A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)","sponsor":"AstraZeneca","enrolled":245,"outcomes":[]},"route":"/trials/nct04538742/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}